A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo.
Фаза 2 – изследване на ефективността и дозировката
Заболявания:
Non-segmental vitiligo
Спонсор: Takeda Development Center Americas Inc.
Налично на:
БГ
Обобщение
Trial status: Authorised
Percent change from baseline in the F-VASI at Week 24, Percent change from baseline in the T-VASI at Week 24, Proportion of participants achieving ≥50% improvement from baseline in F-VASI at Week 24, Proportion of participants achieving ≥50% improvement from baseline in T-VASI at Week 24
Proportion of participants achieving ≥75% improvement from baseline in F-VASI at Week 24.
Описание
Percent change from baseline in the F-VASI at Week 24, Percent change from baseline in the T-VASI at Week 24, Proportion of participants achieving ≥50% improvement from baseline in F-VASI at Week 24, Proportion of participants achieving ≥50% improvement from baseline in T-VASI at Week 24
Кой може да участва
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 144 participants
Интервенции
ZASOCITINIB
Drug
ZASOCITINIB
Drug
White opaque, hard hypromellose capsule, size 3 containing same excipients as TAK-279 active capsule
БГ
EN